WebSep 17, 2024 · After pricing its shares at $19 each — up from the range of $16 to $18 it had stipulated — the shares increased in value by 28% as of 2:30 p.m. on Thursday. The company is developing ... WebSep 16, 2024 · WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, …
IPO Update: Dyne Therapeutics Readies $175 Million IPO
WebDyne Therapeutics, Inc. Financial Information: Market Cap: $707.8mil: Revenues: $0 mil (last 12 months) Net Income $-28.2 mil (last 12 months) IPO Profile: Symbol: DYN: … WebSep 10, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, announced terms for its IPO on Thursday. The … dark shadows lured a top
Dyne Therapeutics (DYN) Stock Price & Analysis - TipRanks
WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebPost IPO equity ... Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... WebMar 20, 2024 · In addition to DYNE-251, Dyne is building a global DMD franchise with preclinical programs for patients with mutations amenable to skipping other exons, including 53, 45 and 44. About Dyne ... bishops bay golf course